Company Profile
Astellas Pharma
— A pharmaceutical company funded by blockbuster small molecules and moving toward ADCs, antibodies, cell therapies, and gene therapies
As as is responsible for search, approval and sales.Pharmaceutical CompanyComment XTANDI, a low-。 prostate cancer treatment agent, accounts for approximately 45% of sales revenue for the 20 year ended March 2026. On the other hand, it is growingAntibody - Drug Conjugate (ADC) PADCEV, antibody VYLO, PEG RNA-based IZE AYHome Candidates under developmentProtein decomposition in tor, T-cell enhancer, AAV gene therapy, cytoIn this article, the company's overall size is limited to one table.What to do in the modalities and who to work withKeep up with primary information.
- As、as Pharma and DDS
- About logo and company name
- Where is this company in the world of drug discovery and DDS?
- Company Size (Concise)
- Drug discovery and DDS resources
- Past Initiatives
- Future plans
- What is DDS?
- Collaboration mapping of drug discovery and DDS
- Technologies, Products and Services
- The risk of this company
- Glossary/Source/Ins ment and Source Response Table
1. As、as Pharma and DDS in 30 seconds
Securities Code 4503Financial Results
Sales 2,212 billion yenADC targeting Nectin-4. 34.8% year-on-year
Therapy/Regeneration and Visibility4 fields as of March 2026
As asThe modalities of "the current head" and "the next head" are differentXTANDI of low、s accounts for ¥9,608 billion out of ¥2,392 billion in sales revenue for the 20 year ending March 2026 FactsHome about 44.9% The calculation of this paperHome The company expects XTANDI sales to be reduced mainly due to the influence of the U.S. Inflation Control Act (IRA, January 2027), The HoleFive "Priority Strategy Products" such as PADCEV(ADC), IZEAAY(PEG RNA aptamer), and VYLOY(antibody)shows plans to fill in FactsHome In other words, reading the drug discovery and DDS of this company isProcess of transferring the main strength to biological preparation and new modalities by low-、 pharmaceutical companiesRead more
2. Logo and company name
Astellas Pharma Inc. is a trademark of Astellas Pharma Inc. In this article, we do not reproduce the generated image.
Images obtained from the official website(White) img/astellas_logo.svg Set as a dark blue background.
Note: Corporate name is Astellas Pharma Inc. Astellas Pharma Inc.Home Astellas US LLC As as Jean Therapy Inc. is a subsidiary of As as Jean Therapy Co., Ltd. and may be a subsidiary of the affiliate contract. The product name is written in the US name (PADCEV, IZEAAY, VYLOY, etc.).
Official Site:https://www.astellas.com/jp/3. Where is this company in the world of drug discovery and DDS?
TypePharmaceutical CompanyComment Securities Report writes the company’s business as “Research and Development, Manufacturing and Sales of Pharmaceuticals,” and segments are only one of the pharmaceutical businesses. FactsHome The main modality is based on salesLow) (XTANDI)in the growth baseAntibody and ADC (PADCEV, VYLOY)Comment In addition, the management plan 2026 of the company includes eight modalities: low, ADCs, immunostimulating ADCs (iADCs), target protein degradation in tumors (TPDs), T-cell enhancers (TCEs), mRNAs, cells and genes. FactsHome This series is handled by most of the types of drug discovery modalities are handled within one company.
4. Company Scope (Concise)
As a major pharmaceutical company, the entire company is listed in one table. Facts。
| Index (IFRS) | FY2025 | FY2026 | Fiscal Year 2027 |
|---|---|---|---|
| Sales revenue | 1,912 billion yen | ¥2,392 billion | 2,200 billion yen |
| R&D expenses (sales revenue ratio) | 3,272 billion yen(17.1 3 | 3,148 billion yen(14.7 3 | 3,550 billion yen(16.0%) |
| Core Operating Income | 3,924 billion yen | JPY5,557 billion | ¥200 billion |
| Capital investment (tangible fixed assets) | ― | 493 billion yen | ― |
| Number of employees | 13,643 people | 14,099 people | ― |
Consolidated Financial Results for the Fiscal Year Ended March 31, 2019 Undetermined / FutureHome "-" is a field that has not confirmed the primary information in this article.
The above numbersCompany OverviewADC, gene therapy, cell therapy, etc.Not disclosed Undetermined / FutureHome Since sales by product are disclosed, in this articleSales by ProductLet’s take a look at what modalities are earning.
5. Drug discovery and DDS resources
| Resource Types | ation | |
|---|---|---|
| Person: Research Center | Tsukuba Business Center (Research equipment, 715 employees), Tsukuba Tokodai Business Center (Research equipment, 181 people), Yaizu Business Center (Research and production equipment, 542 people). Astellas Institute For Innovative Medicines (Massachusetts, R&D, 262) and Astellas Jean Therapy Inc. (California, R&D, 326). As of March 31, 2026 | Facts |
| Number of employees | Total number of R&D departments and number of modalities | Not specified |
| Gold: R&D expenses | JPY3,148 billion (14.7% of revenue) Management Plan 2026: “Base: Average 20% vs. Sales Revenue”, Additional Investment: Up to5%” | Facts |
| Gold: Investment in manufacturing equipment | A new plant of aseptic preparations was built in Trary, Ireland. The total amount of investment is €37,000 million, EUR 2,9800 million, EUR 2024, and JPY 2028. When published in September 2023, it explains that it supports the development and commercialization of new products such as antibody drugs. | Facts |
| External: Acquisition | OccaRx Pharmaceuticals (2016, ophthalmic cytotoxic), OdenusRx Pharmaceuticals (2020, AAV gene therapy), IVERIC bio (July 2023), ophthalmology. Total share value: approx. $59 billion | Facts |
| External: License | Evopoint Biosciences (China) to CLDN18.2 target ADC XNW27011 (May 2025), Vir Biotechnology (USA) and T-cell Enhancer VIR-5500 (February 2026), iADC technology of Sutro Biopharma (USA) (June 2022) | Facts |
| External: Joint valve | A joint venture company that develops the manufacturing platform of Yaskawa Electric Co., Ltd. (Capital 45 billion yen, investment ratio as as 60%, Yaskawa Electric 40%). Name: Serrafa Bioscience | Facts |
| University/Research Organization/Public Fund | Basic Agreement on Drug Startup Support in the “Medical Venture Total Support Project” commissioned by the Ministry of Health, Labour and Welfare (June 2025) and the Basic Agreement on Drug Startup Support Program (July 2025) | Facts |
| Acceptance of public research funds | National research and subsidy | Not specified |
The second item of "No description" was not included in the number of securities reports, financial statements, and management plan 2026. does not mean that there is noIn this article, I can't confirm it with primary information.That means.
6. Past Initiatives
| Time | Home | The meaning of drug discovery and DDS |
|---|---|---|
| April 2005 | Yamanouchi Pharmaceutical Co., Ltd. and Fuji Fuji Pharmaceutical Co., Ltd. merged with As Terra Pharma Inc. | Current Company |
| January 2007 | Agreement between Agensys (acquired in December of the same year) and Seagen (acquired by Pfizer in December 2023) begins with Enhorts Mabuvedotin and ADC technology | ADC joint development leading to PADCEV |
| December 2007 | Acquisition of Agensys, a cancer-based antibody pharmaceutical venture | In-house basis of antibody |
| February 2016 | Acquisition of ophthalmic cyto s (USA) | Research Center for Cell Medicine (currently As Institute For Jean Medicine) |
| December 2016 | Acquisition of Gammed Pharmaceuticals (Germany) | Expanded research foundation for antibody drugs |
| January 2020 | Acquisition of AAV Genetics Therapy Ord Pharma (USA) | Research Center for Therapy (currently As Jean Therapys) |
| June 2022 | Sutro Biopharma (USA) and iADC Technology Agreement | Immune-stimulating ADC technology introduction |
| July 2023 | IVERIC bio($40 share, $59 billion share value) | RNAed IZE AY of PEG RNA aptamer |
| August 2023 | IZE AY acquires U.S. FDA approval (mapped atrophy due to aging ma degeneration) | Nucleic acid intrao (in the glass) |
| September 2023 | A new plant for aseptic preparation was established in Trary, Ireland (approximately 30 million ) | Enhanced production capacity for antibody drugs |
| March 2025 | Established a joint venture company with Yasugawa Electric Co., Ltd. and a joint venture company of the cellular medical manufacturing platform using the robot “Makoro” (established in September 2025). Name: Serrafa Bioscience | Manufacture of cell medicine by robot |
| April and July 2025 | KRAS G12D decomposition induction drug setidegrasib (ASP3082) achieves clinical PoC with pancreatic gland cancer, followed by non-small cell lungs | Protein degradation in clinical trials respond |
| May 2025 | CLd CLDN18.2 target ADC XNW27011 from Evopoint Biosciences. T contract fee US$13,000 million | Aim the same target as VYLOY with ADC |
| November 2025 | PADCEV+ Pembrolizumab approved by the U.S. in preoperative postoperative therapy of cisplatin-inapplicable muscle invasion b、der cancer. Launched IZE AY in Japan | ADC spreads to early stages |
| December 2025 | Cell culture automation system by robot "Mahoro" acquires advanced manufacturing technology of FDA (CBER) | Cell medical manufacturing technology has been designated by regulatory authorities |
| February 2026 | Vir Biotechnology and VIR-5500 (Dual mask type PSMA×CD3 T-cell engager) | Find the following of low- XTANDI with prostate |
| April 2026 | setidegrasib transitions to phase III with pancreatic glands. ASP2957 succeeded to phase I | TPD replaces candidates for gene therapy in the latter half |
| July 2026 | PADCEV+ Pembrolizumab approved by the U.S. postoperative therapy for muscle invasive b、der cancer, regardless of whether or not cisplatin adaptation (Europe approved in June, cisplatin inappropriate) | First approval and company description as a preoperative postoperative therapy that does not use platinum |
Example of clinical trial:V-304 (KEYN -B15)
Summary of Phase III trials based on US approval in July 2026 FactsHome The number is quoted from the company's official announcement,Does not recommend specific treatment。
| Test name | Phase 304/KEYN-B15 (NCT04700124) |
| Adult with cysplatin-adapted muscle-invasive b der to receive full b der removal | |
| PADCEV+Pembrolizumab postoperative administration + surgery vs. gemcitabine + cisplatin preoperative ch therapy + surgery | |
| Main evaluation items | Non-event survival (EFS): 0.53 Hazard ratio (95% confidence interval 0.41–0.70). Estimation of non-event survival rate as of 2 years 79.4% vs 66.2% |
| Main Sub-order Evaluation Items | Total survival: Hazard ratio 0.65 (95% confidence interval 0.48 - 0.89). Pathological complete response at the time of surgery 55.8% vs. 32.5% |
| Safety | Grade 3 or higher adverse events 75.7% vs 67.2% |
| Positioning analysis | In the company document, it is written as "inter」 analysis set in advance" |
7. Future plans
10 or more5 or more of them by FY2027
2x to 2025FY2025 Approx. ¥4,800 billion
About 1 trillion yenNot a company's goal
In the mid 2030s, the company aims to achieve the highest level of revenue in the past. Undetermined / FutureHome As of July 2026, Phase III incorporation began with setidegrasib (non-small cell lung cancer, NCT07566052) and ASP2138 (stomach and esophagus gastric junction gland cancer, NCT07673887). Facts。
| Products | Home | Stage (As of July to August 2026) | |
|---|---|---|---|
| setidegrasib（ASP3082） | KRAS G12D Decomposition Inductor (TPD) | Developed (phase III). Pancreatic gland cancer and non-small cell lung cancer | Undetermined / Future |
| ASP2138 | Anti-CLDN18.2/Anti-CD3 Double-specific antibody (TCE) | Developed (phase III). Gastrointestinal cancer | Undetermined / Future |
| ASP546C（XNW27011） | CLDN18.2 Target ADC | NCT07488676 Evopoint-led Phase III in China | Undetermined / Future |
| VIR-5500 | PSMA×CD3 Double Face Mask Type TCE | Developed (phase I). Prostate Cancer | Undetermined / Future |
| ASP2998 | TROP2 target dual payload iADC | Development (Phase I) | Undetermined / Future |
| ASP5834 | Pan-KRAS Decomposition Inductor (TPD) | Developed (phase I). Non-small cell lungs designated FDA Fast Track | Undetermined / Future |
| AT845／ASP2957 | AAV Therapy | Under development (AT845 is phase II, Pompe disease, ASP2957 is phase I, X-linked myocardiomyopathy) | Undetermined / Future |
| ASP7317 | Retinal pigment epithelial cells (cyto ) | Developed (phase Ib). Clinical PoC achieved with aging ma degeneration with map atrophy | Undetermined / Future |
None of the following are listed in the primary information Undetermined / Future。
per productDate of application and approval(only if you want to go to the city after the 29 year)/ pancreatic gland cancer phase III trial of setidegrasibNCT Number/ Pipeline sales potential "approx. 1 trillion yen"Product/ In the new factory of TraryWhich product to makeHome The sales forecast for each item in the report is not adopted in this article.
8. What is this company aiming for drug discovery and DDS?
This includes parts that the company does not directly state.Calculation in the range that can be read from primary informationand write with the basis.
| Read | Primary Information | |
|---|---|---|
| Attack one target with multiple modalitiesTarget franchise type | Concurrently three antibody (VYLOY), double-specific antibody (ASP2138) and ADC (ASP546C) for CLDN18.2. Management Plan 2026 says “Expanding CLDN18.2 targeted treatment franchises based on VYLOY” | |
| In prostate cancerThe following low-s are sought for biological preparations | Development of prostate cancer is ASP5541 (low ) and VIR-5500 (TCE). VIR-5500 | |
| New modalitiesUse of in-house drug discovery and added valueContact Us | Management Plan 2026 does not pursue the “res type BD” that buys short-term revenue through large acquisitions, and clearly indicates the policy to increase value by in assets with a certain amount of risk. | Facts |
| Cell TherapyMake the difference first with manufacturing technology from the preparation itselfAim | The automatic cultivation system of the robot "Mahuro" acquires the FDA's advanced manufacturing technology designation and explains that the joint venture provides the manufacturing base for startups and universities. | |
| TherapyThe sorting is progressing | Strategic interruption of AT132 (intangible assets loss 166.4 billion yen) and succession of ASP2957 | Facts |
VYLOY is the world's first approved antibody for CLDN18.2. FactsHome Then As、as against the same targetDouble-specific antibody ASP2138to phase III. ADC ASP546C to carry anticancer agentintroduced from Evopoint in China FactsHome Management plan 2026 of gastric and esophagus gastric junction gland cancerCLDN18.2 Low to moderate patient layer (approx. 35%)Home “Future Potential” FactsHome Low-expression tumors that are hard to work alone can reach with ADCs and TCE that can kill cells even with few targets — In other wordsExpand the patient layer by changing the "DDS" to the same targetIf you want to read this article, Undetermined / FutureHome However, the company does not show the policy of use and use of 3 drugs, and this is a guess.
9. Collaboration mapping of drug discovery and DDS
10. Technologies, Products and Services
XTANDIHomeIf you are aligned with: FactsHome Sales will be approved and structured for the20 year ending March 2026.
| Product | modality and structure | FY2026 | |
|---|---|---|---|
| XTANDI | Low androgen receptor in tor | JPY608 billion | Prostate cancer. Decided by the Company in FY2026 |
| PADCEV | ADC. Carried with cystein with a linker that cuts MMAE with pro aur. Drug antibody ratio about 3.8 | JPY212 billion | urinary tract epithelial cancer and myocardial invasive b der cancer. Pfizer |
| IZE AY | RNA aptamers that in t the auxiliary C5 share about 43kDa's RNA PEG. Injection in the glass body | ¥76 billion | Ageing ma degeneration with mapped atrophy. Approved in August 2023, released in November 2025 |
| VYLOY | Anti-CLDN18.2 Meella (mouse/human) IgG1 Antibody | ¥31 billion | Gastric gland cancer and esophagus gastric junction cancer. 30+ countries |
| VEOZAH | Low NK3 receptor antagonist | billion yen | Vas movement neuro ptom accompanying menopause |
| XOSPATA | This article has not confirmed the structure | ¥18 billion | Acute myeloid leukemia |
The total of five key strategic products is ¥4,803 billion, about 22.5% of revenue The calculation of this paperHome ADC (34.8% increase), aptamer (33.2% increase), and antibody (415.6% increase) are higher in the growth rate. FactsHome The mechanism of ADC is handled by nucleic acid drugs, which explains the technology of this series "antibody medicine and ADC", and the concept of nucleic acid, including aptamer, is handled by nucleic acid drugs.
PADCEV Attachments for AntibodyCysteine that returns chain-to-chain di fide bondsHome MMAE joins the MMAE through the maritime kaproil-valin-citorlin (vc) linkerDrug antibody ratio (3.8) Approx. 3.8It is written FactsHome ASP546CPayload in tor topoisomerase I, 8MediLink Explanation of the use of the linker (TMALIN) technology that revitalizes in a microtumor environment FactsHome When doubled the uterus, the drug that can be carried with one molecule is removed, but the hydrophobic payload increasesNon-uniformity when purified and stable in bloodIt is effective to select hydrophilic and bind chemistry of the linker. IZE AY reverses to nucleic acid (aptamer)About 43kDa PEGLarger s It is considered to be a design to stay in the eye for a long time, but the management of the weight distribution and binding position of PEG becomes the work of the material and process side Undetermined / Future。
11. Risks that this company has
| Risks | ||
|---|---|---|
| XTANDI Dependency and Re treatment | About 44.9% of sales revenue is XTANDI. The company expects a reduction of approximately 500 billion yen in FY2026 (mainly the impact of IRA in the U.S., January 2027) | Facts |
| Disco ed Development | In the strategic year ending March 2026, a strategic interruption of gene therapy AT132 recorded a loss of 16 billion yen in intangible assets and a loss of 1.2 billion yen in Xyphos related programs. ASP1012, ASP1570, ASP4ASP, ASP5502. | Facts |
| Key ADC Partnership Structure | PADCEV is a joint project in which Pfizer estimates U.S. sales. The company indicates peak sales forecasts as 'Total product sales instead of As's sales'. | Facts |
| Regional Restrictions on the Rights of Products | ASP546C’s rights are all over the world except China mainland, Hong Kong, Macao and Taiwan. Development in China led lead Evopoint | Facts |
| Second term development | Plans that depend on the results of the 10 or more phase III/pivotar trials, set the starting point of growth as "FY2029". | Undetermined / Future |
| Launch of new modalities | ADC of cyto , gene therapy and high blood pressure affects the quality of the manufacturing method itself. 2028 Completed | |
| Invisible investment by modalities | Non-dis sure of modalities separate breakdown of R&D expenses, making it difficult to verify the validity of distribution from outside | Undetermined / Future |
12. Glossary
- ADC
- A drug that connects anticancer agent (payload) with a linker. Antibody carries drugs to target cells.
- (Drug antibody ratio)
- The average number of payloads combined per of antibodies. PADCEV 3.8
- Aptamer
- Short nucleic acids (RNAs and DNAs) selected to join certain proteins. IZE AY is a RNA aptamer with PEG.
- PEG
- Sharing poly l into medicine. It is used to extend the time to stay in the body by increasing the .
- T-Cell Enhancer (TCE)
- Double-specific antibodies that bind cancer cells to both the mark and CD3 of T cells and attack cancer cells to T cells.
- Target protein decomposition in tor (TPD)
- A drug that causes the cause of the disease to the mechanism of decomposition in the cells.
- AAV Therapy
- Treatment to deliver missing genes to cells by carrying the adenos accompanying virus.
- Clinical PoC
- Concept verification. The company calls this stage to confirm the signs of effects targeted by humans.
- CLDN18.2
- Claudin 18.2. Common target of VYLOY, ASP2138 and ASP546C with protein on the cell surface such as gastric cancer.
Concept diagram of AI generation13. Source
- As as Pharma Financial Results for the Fiscal Year Ended March 31, 2026 History, business content, management important contracts, R&D activities, equipment status, employees, and revenue trends. https://www.astellas.com/content/dam/astellas-com/global/ja/confidential-documents/securities-report/annual-securities-report-fy2025-jp.pdf
- As as Pharma Consolidated Financial Results for the Fiscal Year Ending March 31, 2026 (April 27, 2026). Sales revenue, R&D expenses, sales of major products, loss of loss of loss, and business forecast for the、20 year ended March 31, 2027. https://www.astellas.com/content/dam/astellas-com/global/ja/confidential-documents/financial-results/4q2025_jp.pdf
- As as Pharma Financial Results for FY2025 (April 27, 2026). Forecast for FY2026, pipeline modalities, trials, peak sales forecast. https://www.astellas.com/content/dam/astellas-com/global/ja/confidential-documents/financial-results/4q2025_pre_jp.pdf
- As as Pharma Management Plan 2026 Presentation Material (May 26, 2026). Result indicator, modalities, R&D policy, business development policy, CLDN18.2 franchise. https://www.astellas.com/content/dam/astellas-com/global/ja/confidential-documents/investors-meeting/astellas_csp2026_presentation_20260526_jp.pdf
- As as Pharma Press Release 'Economic rate 2026 Management Plan for Sustainable Growth to Deliver Greater Values' (May 26, 2026) https://jp.newsroom.astellas.com/2026-05-26-astellas-announces-five-year-corporate-strategic-plan-to-deliver-greater-value-faster-for-patients-and-position-itself-as-a-sustainable-growth-company
- As as Pharma Financial Results for the First Quarter of FY2026 (August 5, 2026). Incorporation of phase III trial (NCT number), ASP546C structure and scope of rights, PADCEV European approval. https://www.astellas.com/content/dam/astellas-com/global/ja/confidential-documents/financial-results/1q2026_pre_jp.pdf
- Astellas Pharma “Astellas Enters into Definitive Agreement to Bio Iveric Bio” (April 30, 2023). US$40 per share, US$59 billion per share https://newsroom.astellas.com/2023-04-30-Astellas-Enters-into-Definitive-Agreement-to-Acquire-Iveric-Bio
- Astellas Pharma FDA Approval for IZE BioAY (avacincaptad gol intravitreal solution) https://newsroom.astellas.com/2023-08-05-Iveric-Bio-Receives-U-S-FDA-Approval-for-IZERVAY-TM-avacincaptad-pegol-intravitreal-solution-,-a-New-Treatment-for-Geographic-Atrophy
- National Library of Medicine DailyMed IZE AY (avacincaptad gol) US attachment. Structure of RNA PEG of about 43kDa with RNA aptamer. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1642fe6a-dc26-4d20-ae6e-654af744e3bd
- National Library of Medicine DailyMed PADCEV (enfortumab vedotin-ejfv) US attachment. Antibody, linker, MMAE, and drug antibody ratio 3.8. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b5631d3e-4604-4363-8f20-11dfc5a4a8ed
- Pfizer・Astellas Pharma ‘U.S. FDA Approves PADCEV plus Key Keyda as Muscleadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility’ (July 13, 2026). Clinical trial partnership with Merck as a result of the 304 trial. https://newsroom.astellas.com/2026-07-13-us-fda-approves-padcev-plus-keytruda-as-neoadjuvant-and-adjuvant-treatment-for-muscle-invasive-bladder-cancer-regardless-of-cisplatin-eligibility
- Astellas Pharma・Evopoint Biosciences “Astellas Enters License Agreement with Evopoint Biosciences for XNW27011” (May 30, 2025). U.S. dollar 1 trillion. https://newsroom.astellas.com/2025-05-30-Astellas-Enters-Exclusive-License-Agreement-with-Evopoint-Biosciences-for-XNW27011,-a-Novel-Clinical-stage-Antibody-Drug-Conjugate-Targeting-CLDN18-2
- Astellas Pharma・Vir Biotechnology “Astellas and Vir Biotechnology Announce Global Collaboration to Advance PSMA-targeting PRO-XTEN Dual-masked T-Cell)ager VIR-5500” (February 23, 2026). Terms and Conditions https://newsroom.astellas.com/2026-02-24-astellas-and-vir-biotechnology-announce-global-strategic-collaboration-to-advance-psma-targeting-pro-xten-r-dual-masked-t-cell-engager-vir-5500-for-the-treatment-of-prostate-cancer
- Astellas Pharma “Astellas and YASKAWA Agree to a Joint Venture Focused on Cell Therapy Manufacturing” Capital 45 billion yen, investment ratio 60%/40%. https://newsroom.astellas.com/2025-03-06-Astellas-and-YASKAWA-Agree-to-Establish-a-Joint-Venture-Focused-on-Cell-Therapy-Manufacturing
- Astellas Pharma “Astellas Receives Advanced Manufacturing Technology Designation by U.S. FDA for Maholo Robotic Cell Culture Automation System” https://newsroom.astellas.com/2025-12-18-astellas-receives-advanced-manufacturing-technology-designation-by-u-s-fda-for-maholo-robotic-cell-culture-automation-system
- Astellas Pharma “Astellas to Invest more than €330 Million in a New State-of-the-Art Facility in Tralee, Co. Kerry, Ireland” (September 14, 2023). New products such as a new plant of aseptic preparation and antibody medicine. https://newsroom.astellas.com/2023-09-14-Astellas-to-Invest-more-than-EUR330-Million-in-a-New-State-of-the-Art-Facility-in-Tralee,-Co-Kerry-Ireland
- National Library of Medicine DailyMed XTANDI (。lutamide) classification and chemical structure as an androgen receptor in tor. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b129fdc9-1d8e-425c-a5a9-8a2ed36dfbdf
- National Library of Medicine DailyMed VEOZAH (fezolinetant) US attachment. Low。 NK3 receptor antagonist. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cae9f798-24f9-4580-a4fc-e6c710cbda3c
- National Library of Medicine DailyMed VYLOY (zolbetuximab-clzb) US attachment. Imera (mouse/human) IgG1 antibody. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e7695a21-abb6-47ac-93f8-0ece5a9c4409
- As as Pharma Official website (for confirmation of company profile and logo) https://www.astellas.com/jp/
14. Response table of claims and sources
| Content | ||
|---|---|---|
| Formal name, head office location, established by merger in April 2005, content of business (R&D, manufacturing and sales, single segment) | Facts | Source 1 https://www.astellas.com/content/dam/astellas-com/global/ja/confidential-documents/securities-report/annual-securities-report-fy2025-jp.pdf |
| Listed on the Tokyo Stock Exchange, Securities Code 4503 | Facts | Source 2 https://www.astellas.com/content/dam/astellas-com/global/ja/confidential-documents/financial-results/4q2025_jp.pdf |
| Sales revenue, R&D costs, core operating income (fiscal year 2025 and March 2026), sales of key products, loss of loss of loss (AT132 166.4 billion, Xyphos related 1.2 billion) | Facts | Source 2 https://www.astellas.com/content/dam/astellas-com/global/ja/confidential-documents/financial-results/4q2025_jp.pdf |
| The impact of the company forecast for the fiscal year ending March 2027 (e.g., 22,200 billion yen in sales revenue, 3,550 billion yen in research and development, 6,200 billion yen in core operating income) and XTANDI | Undetermined / Future | Source 3 https://www.astellas.com/content/dam/astellas-com/global/ja/confidential-documents/financial-results/4q2025_pre_jp.pdf |
| Number of employees (consolidated: 14,099, number of employees at each business and research subsidiary) | Facts | Source 1 https://www.astellas.com/content/dam/astellas-com/global/ja/confidential-documents/securities-report/annual-securities-report-fy2025-jp.pdf |
| Total investment plan for the new TRARI factory is expected to be completed in 2028. | Facts | Source 1 https://www.astellas.com/content/dam/astellas-com/global/ja/confidential-documents/securities-report/annual-securities-report-fy2025-jp.pdf |
| Trary’s new plant is an aseptic plant that supports new products such as antibody drugs (September 2023, about 30 million ) | Facts | Source16 https://newsroom.astellas.com/2023-09-14-Astellas-to-Invest-more-than-EUR330-Million-in-a-New-State-of-the-Art-Facility-in-Tralee,-Co-Kerry-Ireland |
| Agreement with Seagen Sutro Evopoint | Facts | Source 1 https://www.astellas.com/content/dam/astellas-com/global/ja/confidential-documents/securities-report/annual-securities-report-fy2025-jp.pdf |
| Primary Focus 4 field, clinical PoC, phase transition, disco・ation of development, and partnership with cancer research group | Facts | Source 1 https://www.astellas.com/content/dam/astellas-com/global/ja/confidential-documents/securities-report/annual-securities-report-fy2025-jp.pdf |
| Acquisition of IVERIC bio (USD 40 per share, USD 59 billion) | Facts | Source 7 https://newsroom.astellas.com/2023-04-30-Astellas-Enters-into-Definitive-Agreement-to-Acquire-Iveric-Bio |
| IZE AY U.S. approval (August 4, 2023) | Facts | Source 8 https://newsroom.astellas.com/2023-08-05-Iveric-Bio-Receives-U-S-FDA-Approval-for-IZERVAY-TM-avacincaptad-pegol-intravitreal-solution-,-a-New-Treatment-for-Geographic-Atrophy |
| Structure of IZE AY (complex C5 inhibition, RNA marker, RNAPEG of about 43kDa) | Facts | Source 9 https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1642fe6a-dc26-4d20-ae6e-654af744e3bd |
| PADCEV structure (anti-Nectin-4 IgG1, vc linker, MMAE, cysteine binding, 3.8 about 3.8) | Facts | Source10 https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b5631d3e-4604-4363-8f20-11dfc5a4a8ed |
| PADCEV+ Pembrolizumab's U.S. approval (November 2025, July 2026), 304 trial design and resulting in a clinical trial partnership with Merck | Facts | Source11 https://newsroom.astellas.com/2026-07-13-us-fda-approves-padcev-plus-keytruda-as-neoadjuvant-and-adjuvant-treatment-for-muscle-invasive-bladder-cancer-regardless-of-cisplatin-eligibility |
| The result of the 304 is 'preset intermediate analysis', list of tests | Facts | Source 3 https://www.astellas.com/content/dam/astellas-com/global/ja/confidential-documents/financial-results/4q2025_pre_jp.pdf |
| Introduction of XNW27011 (ASP546C), scope of rights and contract fee of USD 13,000 million | Facts | Source12 https://newsroom.astellas.com/2025-05-30-Astellas-Enters-Exclusive-License-Agreement-with-Evopoint-Biosciences-for-XNW27011,-a-Novel-Clinical-stage-Antibody-Drug-Conjugate-Targeting-CLDN18-2 |
| ASP546C payload 8 TMALIN linker, NCT number of phase III trial, PADCEV European approval (June 2026) | Facts | Source 6 https://www.astellas.com/content/dam/astellas-com/global/ja/confidential-documents/financial-results/1q2026_pre_jp.pdf |
| Joint development agreement of VIR-5500 (February 2026) | Facts | Reference13 https://newsroom.astellas.com/2026-02-24-astellas-and-vir-biotechnology-announce-global-strategic-collaboration-to-advance-psma-targeting-pro-xten-r-dual-masked-t-cell-engager-vir-5500-for-the-treatment-of-prostate-cancer |
| Joint Venture with Yaskawa Electric Co., Ltd. (Capital 45 billion yen, 60%/40%) | Facts | Reference14 https://newsroom.astellas.com/2025-03-06-Astellas-and-YASKAWA-Agree-to-Establish-a-Joint-Venture-Focused-on-Cell-Therapy-Manufacturing |
| Mahoro Cell Culture Automation System Receives FDA Advanced Manufacturing Technology Designation | Facts | Source15 https://newsroom.astellas.com/2025-12-18-astellas-receives-advanced-manufacturing-technology-designation-by-u-s-fda-for-maholo-robotic-cell-culture-automation-system |
| Management Plan 2026 Results Indicator, R&D Policy, Value Additive BD, CLDN18.2 Patient Layer, pipeline modalities | Facts | Source 4・5 https://www.astellas.com/content/dam/astellas-com/global/ja/confidential-documents/investors-meeting/astellas_csp2026_presentation_20260526_jp.pdf |
| Growth from FY2029 and JPY1 trillion | Undetermined / Future | Source 5. Not a company's goal https://jp.newsroom.astellas.com/2026-05-26-astellas-announces-five-year-corporate-strategic-plan-to-deliver-greater-value-faster-for-patients-and-position-itself-as-a-sustainable-growth-company |
| XTANDI・VEOZAH・VYLOY | Facts | Source 17・18・19 https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b129fdc9-1d8e-425c-a5a9-8a2ed36dfbdf |
| XTANDI is about 44.9% of sales revenue and about 22.5% of 5 key strategic products | The calculation of this paper | ulation of this article divided by product sales by source 2 with revenue of 2,392 billion yen |
| Classification of type 3 (pharmaceu) company / drug discovery biotech / contract development manufacturing / research) | The calculation of this paper | This article does not specify the company name. The company name is an example from the series of companies in this article. |
| Modality’s R&D expenses, R&D personnel, and receipt of public research funds | Undetermined / Future | Not specified in the source 1-4. This article does not estimate |
| Production items of setidegrasib pancreatic gland cancer phase III NCT number and trary new plant | Undetermined / Future | The source is not specified in this article. |
| Aiming to reach low-current ADC and TCE | Interpre of this paper from the description of source 4 and 12 | |
| Read that the prostate is seeking the next of low s in biological formulations | Interpre of this article from the description of source 4 and 13 | |
| Cell medical care is the first step in manufacturing technology. | Interpre of this paper from the description of the source 14 and 15 | |
| ADCs and PEG-based aptamers for high-efficiency materials and processes, and the risk of manufacturing new modalities | Explanation of this article from the description of the structure of the source 6, 9, 10 |
Last Updated:September 26, 2026/Troy Technical
The figures in this article are based on Astellas' securities reports, financial statements, management plans, official press releases, and dailyMed. We do not use estimates and media-based numbers from survey companies. The 'ulation' section is an interpretation that the article reads from the primary information and is not an announcement of the company. This article is not intended for medical advice, but does not recommend the use of certain drugs.